



Disease Modifying Therapies for the Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Effectiveness and Value

Friday • September 20, 2024 • 10:00 AM – 4:00 PM CT

Virtual Event – Zoom Webinar

Registration: https://events.zoom.us/j/7z0Nm9gg7YY38_y0SDmOA906P25Sr99risQ

Time (CT)	Activity
10:00 AM – 10:20 AM	Meeting Convened and Opening Remarks Sarah K. Emond, MPP President and CEO, ICER Steven D. Pearson, MD, MSc Special Advisor, ICER
10:20 AM – 11:00 AM	Presentation of the Clinical Evidence Jason H. Wasfy, MD, MPhil Associate Professor, Harvard Medical School Director of Outcomes Research and Cardiologist, Massachusetts General Hospital Heart Center
11:00 AM – 11:40 AM	Presentation of the Economic Model Aaron, Winn, MPP, PhD Associate Professor, University of Illinois at Chicago
11:40 AM – 12:00 PM	Public Comments and Discussion
12:00 PM – 12:50 PM	Lunch Break
12:50 PM – 1:50 PM	Midwest CEPAC Vote on Clinical Effectiveness and Value
1:50 PM – 2:00 PM	Break
2:00 PM – 3:30 PM	Policy Roundtable
3:30 PM – 4:00 PM	Reflections from Midwest CEPAC
4:00 PM	Meeting Adjourned